Table 2. Frequency (%) of Presenting... | American Society of Hematology

Table 2.

Frequency (%) of Presenting Features and Outcome in Infants With ALL According to Prednisone Response (n = 105)

Feature	PGR (n = 78)		PPR (n = 27)		P Value
Feature	%	pEFS ± SE (%)	%	pEFS ± SE (%)	P Value
Sex
Female	53	54 ± 13	48	23 ± 12	.008
Male	47	52 ± 9	52	7 ± 7	.0003
Age (mo)
<6	51	44 ± 8	52	0 ± 0	.0001
≥6 ≤ 12	49	64 ± 8	48	31 ± 13	.01
WBC (×10³/μL)
<100	51	54 ± 9	22	33 ± 19	.24
≥100	49	52 ± 8	78	10 ± 6	.0002
CNS disease
Present	22	28 ± 11	30	0 ± 0	.17
Absent	78	60 ± 7	70	22 ± 10	.0002
Immunophenotype^*
CD10
Negative	57	49 ± 8	63	0 ± 0	.0001
Positive	43	59 ± 9	37	40 ± 15	.14
Myeloid marker
Present	28	45 ± 12	30	25 ± 15	.16
Absent	72	57 ± 7	70	11 ± 7	.0001
Cytogenetics^†
Normal (n)	42 (16)	60 ± 13	10 (2)	0 ± 0	.02
11q23 rearranged (n)	45 (17)	41 ± 12	55 (11)	9 ± 9	.03
t(4;11) (n)^‡	(9)	33 ± 16	(7)	0 ± 0	.06
Other aberrations (n)	13 (5)	100 ± 0	35 (7)	40 ± 22	.22

Feature	PGR (n = 78)		PPR (n = 27)		P Value
Feature	%	pEFS ± SE (%)	%	pEFS ± SE (%)	P Value
Sex
Female	53	54 ± 13	48	23 ± 12	.008
Male	47	52 ± 9	52	7 ± 7	.0003
Age (mo)
<6	51	44 ± 8	52	0 ± 0	.0001
≥6 ≤ 12	49	64 ± 8	48	31 ± 13	.01
WBC (×10³/μL)
<100	51	54 ± 9	22	33 ± 19	.24
≥100	49	52 ± 8	78	10 ± 6	.0002
CNS disease
Present	22	28 ± 11	30	0 ± 0	.17
Absent	78	60 ± 7	70	22 ± 10	.0002
Immunophenotype^*
CD10
Negative	57	49 ± 8	63	0 ± 0	.0001
Positive	43	59 ± 9	37	40 ± 15	.14
Myeloid marker
Present	28	45 ± 12	30	25 ± 15	.16
Absent	72	57 ± 7	70	11 ± 7	.0001
Cytogenetics^†
Normal (n)	42 (16)	60 ± 13	10 (2)	0 ± 0	.02
11q23 rearranged (n)	45 (17)	41 ± 12	55 (11)	9 ± 9	.03
t(4;11) (n)^‡	(9)	33 ± 16	(7)	0 ± 0	.06
Other aberrations (n)	13 (5)	100 ± 0	35 (7)	40 ± 22	.22

Percentage of evaluated infants (n = 104).

Percentage of evaluated infants (n = 58; PGR, n = 38; PPR, n = 20).

Patients included in 11q23 rearranged.